AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
…, P Ballard, K Al-Kadhimi, R Rowlinson, T Klinowska… - Cancer discovery, 2014 - AACR
First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
…, D Baker, MJ Mellor, AN Brooks, T Klinowska - Cancer research, 2012 - AACR
The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis
and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are …
and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are …
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
…, GB Hill, D James, M James, P Kemmitt, T Klinowska… - 2014 - ACS Publications
Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the
treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or …
treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or …
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
…, E de Stanchina, DG Barratt, S Cosulich, T Klinowska… - Nature, 2016 - nature.com
Precision medicines exert selective pressure on tumour cells that leads to the preferential
growth of resistant subpopulations, necessitating the development of next-generation …
growth of resistant subpopulations, necessitating the development of next-generation …
Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
RA Ward, MJ Anderton, S Ashton… - Journal of medicinal …, 2013 - ACS Publications
A novel series of small-molecule inhibitors has been developed to target the double mutant
form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to …
form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to …
[HTML][HTML] Further evidence to support the melanocytic origin of MDA-MB-435
G Ellison, T Klinowska, RFR Westwood… - Molecular …, 2002 - ncbi.nlm.nih.gov
Background/Aims: Until recently, the cell line MDA-MB-435 was widely accepted as
originating from a breast cancer. However, microarray derived data have suggested that this …
originating from a breast cancer. However, microarray derived data have suggested that this …
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
…, Z Howard, BR Davies, G Bigley, T Klinowska… - Molecular cancer …, 2015 - AACR
Abstract mTOR is an atypical serine threonine kinase involved in regulating major cellular
functions, such as nutrients sensing, growth, and proliferation. mTOR is part of the …
functions, such as nutrients sensing, growth, and proliferation. mTOR is part of the …
Laminin and β1 integrins are crucial for normal mammary gland development in the mouse
TCM Klinowska, JV Soriano, GM Edwards… - Developmental …, 1999 - Elsevier
We have examined the role of integrin–extracellular matrix interactions in the
morphogenesis of ductal structures in vivo using the developing mouse mammary gland as …
morphogenesis of ductal structures in vivo using the developing mouse mammary gland as …
Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist
…, T Johnson, S Kavanagh, T Klinowska… - Journal of Medicinal …, 2020 - ACS Publications
Herein we report the optimization of a series of tricyclic indazoles as selective estrogen
receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer …
receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer …
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB …
DM Hickinson, T Klinowska, G Speake, J Vincent… - Clinical Cancer …, 2010 - AACR
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth
factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and …
factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and …